PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
2.22%
Growth of 2.22% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
2.69%
Cost growth of 2.69% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
0.43%
Positive growth while Medical - Pharmaceuticals median is negative. Peter Lynch would examine competitive advantages.
-1.75%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.01%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-0.35%
Operating expenses reduction while Medical - Pharmaceuticals median is 0.48%. Seth Klarman would investigate advantages.
2.14%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 0.51%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
4.61%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.03%. Jim Chanos would check for overinvestment.
4.16%
EBITDA growth 1.25-1.5x Medical - Pharmaceuticals median of 2.90%. Mohnish Pabrai would examine sustainability.
1.89%
EBITDA margin growth below 50% of Medical - Pharmaceuticals median of 3.79%. Jim Chanos would check for deterioration.
4.58%
Operating income growth near Medical - Pharmaceuticals median of 4.39%. Charlie Munger would verify industry dynamics.
2.31%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.35%. Joel Greenblatt would investigate advantages.
-1.72%
Other expenses reduction while Medical - Pharmaceuticals median is 20.03%. Seth Klarman would investigate advantages.
3.97%
Pre-tax income growth near Medical - Pharmaceuticals median of 3.98%. Charlie Munger would verify industry dynamics.
1.71%
Pre-tax margin growth 50-75% of Medical - Pharmaceuticals median of 2.87%. Guy Spier would scrutinize operations.
4.95%
Tax expense change of 4.95% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
3.45%
Net income growth near Medical - Pharmaceuticals median of 3.14%. Charlie Munger would verify industry dynamics.
1.20%
Net margin growth 1.25-1.5x Medical - Pharmaceuticals median of 0.98%. Mohnish Pabrai would examine sustainability.
3.44%
EPS growth 75-90% of Medical - Pharmaceuticals median of 3.99%. John Neff would investigate potential.
3.44%
Diluted EPS growth 75-90% of Medical - Pharmaceuticals median of 3.99%. John Neff would investigate potential.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.11%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would investigate strategy.